Abstract

AimTo assess the responsiveness, concurrent validity, and feasibility of the Dyskinesia Impairment Scale (DIS) in non‐ambulatory patients with dyskinetic cerebral palsy (CP).MethodThe study is a secondary analysis of data collected in the IDYS trial, a randomized controlled trial on the effects of intrathecal baclofen (ITB). The DIS and Barry–Albright Dystonia Scale (BADS) were conducted at baseline and after 3 months of ITB or placebo treatment. Responsiveness was assessed by comparing the effect sizes and correlation of change after treatment between the DIS and BADS. Concurrent validity was evaluated by assessing the correlations between scales. Feasibility was evaluated for each DIS item by the number of participants who successfully accomplished the item.ResultsThirty‐three non‐ambulatory patients (9 females, 24 males) with dyskinetic CP (ITB‐treated: n=17, mean [SD] age: 14y 1mo [4y 1mo]; placebo‐treated: n=16, mean [SD] age: 14y 7mo [4y]) were included in the study. The effect sizes for BADS and DIS were similar in The ITB‐treated group (−0.29 and −0.22 respectively). Changes after treatment on the DIS dystonia subscale correlated with changes on the BADS (r=0.64; p<0.001). The DIS dystonia subscale and BADS correlated at baseline and follow‐up (r=0.78; p<0.001 and r=0.79; p<0.001). Not all DIS activity items could be performed in this sample of patients.InterpretationFor non‐ambulatory patients with dyskinetic CP, the responsiveness of the DIS equalled the responsiveness of BADS. Concurrent validity was adequate. Feasibility for activity items was restricted in patients with severe dyskinetic CP.What this paper adds The Dyskinesia Impairment Scale (DIS) and Barry–Albright Dystonia Scale showed similar responsiveness in non‐ambulatory patients with dyskinetic cerebral palsy (CP).No floor or ceiling effect was observed for DIS in non‐ambulatory participants.The concurrent validity of DIS was adequate in non‐ambulatory participants.Patients with dyskinetic CP in Gross Motor Function Classification System levels IV and V could not perform all DIS activity items.

Highlights

  • HELGA HABERFEHLNER1 | LAURA A BONOUVRIE1 | KARIN BOESCHOTEN1 | SABINE FLEUREN2 | ELEGAST MONBALIU3 | JULES G BECHER1 | R JEROEN VERMEULEN2 | ANNEMIEKE I BUIZER1

  • Concurrent validity To establish the concurrent validity of the Dyskinesia Impairment Scale (DIS), we considered the score of the DIS and the score for the criterion standard (i.e. Barry–Albright Dystonia Scale (BADS)) at the same time point, that is, at baseline and follow-up.[21]

  • Participants The DIS and BADS scores were available at both time points for 33 (9 females, 24 males) of the 36 participants from the IDYS trial (17 in the intrathecal baclofen (ITB)-treated group mean [SD] age: 14y 1mo [4y 1mo] and 16 in the placebo-treated group; mean [SD] age: 14y 7mo [4y])

Read more

Summary

Objectives

The primary aim of the present study was to assess the responsiveness of the DIS

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call